Trans-activating crRNA (tracrRNA) 1

[{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea21/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea21/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea20/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea20/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea1f/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea1f/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea1e/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea1e/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea1d/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea1d/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea1c/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea1c/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea1b/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea1b/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea1a/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea1a/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea19/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea19/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea18/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea18/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea17/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea17/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea16/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea16/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea15/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea15/5cbf847437bbd33300faea13.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84b837bbd33300faea14/5cbf847437bbd33300faea13.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84b837bbd33300faea14/5cbf847437bbd33300faea13.png"}]